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Cyclosporin A and Kidney Transplantation: Present 
Status of a Partially Randomized Trial 
G. B. G. Klintmalm. T. E. Starzl. S. Iwatsuki. and T. Hakala 
REPORTS concerning the use of Cyclos-porin A (CY-A) in kidney transplanta-
tion in non randomized trials with consider-
able numbers of patients and long follow-up 
have been presented by several centers, some 
with exciting results,I.' some with less exciting 
results.JA Randomized trials have been under 
way for a more limited time, and it is not until 
recently that the first report was made.s This 
is an update of the trial conducted at the 
University of Pittsburgh. 
MATERIALS AND METHODS 
Between March and August 1981.40 patients received 
primary kidney transplants. By randomization. and six 
compassionate releases. 21 patients were treated with 
CY -A and prednisone (Pred), and 19 with azathioprine 
(Aza) and Pred. Parallel to the partially randomized trial 
in primary cadaver kidney transplantation. a nonrandom-
ized trial was conducted using the following described 
CY-A-Pred protocol alone in patients being retrans-
planted. Twenty-two patients received their second or 
third graft. 
Prior to the transplant. all primary graft recipients 
were given at least three blood transfusions. In all recip-
ients. some attempts were made to match donors and 
recipients, resulting in a HLA-A.B match of 1.3 :!: 1.3 
(SO). The DR matching was random. The recipients were 
8-{)4 years of age. with a mean of 33 years. 
The CY-A and Pred treatment principles were as 
follows: CY-A was given 17.5 mg/kg/day orally as one 
dose prior to the transplant. This dose was then main-
tained postoperatively. half of the dose being given every 
12 hr. Reductions of this dose were made at the occur-
rence of toxicity. One gram of methylprednisolone was 
given i.v. during the transplantation. Postoperatively. 
prednisolone was administered 200 mg/day with daily 
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reductions of 40 mg/day until day 6. when 20 mg/day' 
was given. This was the maintenance dose for 2 months, , 
whereafter the prednisolone was reduced to 10 mg/day if. 
kidney function was satisfactory, In face of rejection. the 
intravenoius and oral steroid schedule described was' 
repeated. The treatment is described in detail elsewhere.' 
The Aza- and Pred- treated patients were treated in the 
customary way for kidney transplantation at the Univer-
sity of Pittsburgh :-.1edical School. 
RESULTS 
PartialJy Randomi:ed Patients 
In 21, the primary cadaveric graft r"r·,"'::'._ 
ients receiving treatment with CY-A 
Pred. only one kidney has been lost. This 
due to an accidental donation of a blood 
A kidney to a blood group 0 recipient. 
ing in a renal vein thrombosis. 
In 19. the primary cadaveric 
treated with Aza and Pred, six (32%) 
have been lost to date. 
Nonrandomi:ed Patients ' 
Of the 21 patients that have been 
planted, three (14%) have lost their g 
Two of the grafts were lost by rejection. 
one by a technical error resulting 
artery thrombosis. 
Mortality and Morbidity 
There have been no deaths in any of 
patient groups. A pneumocystis carinii ' 
tion has occurred in one of the primary 
recipients treated with CY -A and Pred. 
infection has been successfully treated 
antibiotics. 
Tabl.1. Follow-Up at 0.5-6.5 Months 
Randomized 
(Primary Cadaveric 
Transp'antsl 
CY-A Azathioprine 
Transplants 21 19 
Lost grafts 1 6 4 
Mortality 0 0 0 
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DISCUSSION 
The interpretation of these results must be 
cautiously because of the short follow-
up (2 weeks to 6'/2 months). Still. it excites 
high hopes in CY -A as a major immunosup-
ive agent for the future. 
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